Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Jivi and Adynovi in Severe Hemophilia A
NCT04015492Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2019
- Primary completion
- Oct 2019
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of damoctocog alfa pegol in hemophilia A (2 arms), sponsored by Bayer. Primary endpoints: Area under the concentration versus time curve from time 0 to the last data point for BAY 94-9027 and Area under the concentration versus time curve from time 0 to the last data point for Adynovi. Started Aug 2019; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04015492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015492.